This is a grant renewal for studies on formulations of high molecular weight (MW>100 Daltons) pharmaceutical agents, such as DNA. Specifically, we plan to apply our understanding and experience in protein stabilization and controlled release system to the stabilization and controlled release of plasmid DNA. The significance of controlled release DNA lies in the significance of gene therapy. Currently, there are almost 400 gene therapy protocols. In clinical trials worldwide spanning a range of disease states (e.g., cancer, monogenic diseases, infectious diseases). The safe and effective delivery of gene therapeutics remains elusive and is currently a bottleneck for gene delivery. The stabilization of DNA in viable long-term pharmaceutical preparations is one critical part toward the advance of gene therapy to the clinic. There is a clear lack of understanding of the physical and chemical degradation of plasmid DNA in pharmaceutical systems, particularly with respect to degradation within hydrophobic polymer matrices. It is necessary to understand the relationship among plasmid DNA degradation pathways that occur under these conditions to begin designing rational methods for their stabilization. Therefore, our Specific Aims are: 1) Identify the principal non-enzymatic degradation pathways of supercoiled, nicked and linear plasmid DNA as a function of dehydration method, DNA packing, DNA hydration, and DNA conformation, (2) Identify new DNA stabilizing excipients or excipient combinations, 3) identify the principal non- enzymatic degradation pathways of supercoiled, nicked and linear plasmid DNA degradation in fully hydrated polymer-based controlled release systems,, the DNA-containing systems will be placed under a wide range of pharmaceutically relevant conditions and the degradation patterns identified by established analytical tools. The long-term objectives of this research are to develop robust DNA stabilization methods to meet the pharmaceutical requirements for controlled release gene delivery systems.
| Bartelt, Alexander; Widenmaier, Scott B; Schlein, Christian et al. (2018) Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity. Nat Med 24:292-303 |
| Kirtane, Ameya R; Abouzid, Omar; Minahan, Daniel et al. (2018) Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. Nat Commun 9:2 |
| Mimee, Mark; Nadeau, Phillip; Hayward, Alison et al. (2018) An ingestible bacterial-electronic system to monitor gastrointestinal health. Science 360:915-918 |
| Tong, Zhixiang; Martyn, Keir; Yang, Andy et al. (2018) Towards a defined ECM and small molecule based monolayer culture system for the expansion of mouse and human intestinal stem cells. Biomaterials 154:60-73 |
| DiCiccio, Angela M; Lee, Young-Ah Lucy; Glettig, Dean L et al. (2018) Caffeine-catalyzed gels. Biomaterials 170:127-135 |
| Lo, Justin H; Hao, Liangliang; Muzumdar, Mandar D et al. (2018) iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 17:2377-2388 |
| Caffarel-Salvador, Ester; Abramson, Alex; Langer, Robert et al. (2017) Oral delivery of biologics using drug-device combinations. Curr Opin Pharmacol 36:8-13 |
| Nadeau, Phillip; El-Damak, Dina; Glettig, Dean et al. (2017) Prolonged energy harvesting for ingestible devices. Nat Biomed Eng 1: |
| Doloff, Joshua C; Veiseh, Omid; Vegas, Arturo J et al. (2017) Colony stimulating factor-1 receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates. Nat Mater 16:671-680 |
| Liu, Jinyao; Pang, Yan; Zhang, Shiyi et al. (2017) Triggerable tough hydrogels for gastric resident dosage forms. Nat Commun 8:124 |
Showing the most recent 10 out of 125 publications
